Direkt zum Inhalt
Merck

SAB4200047

Sigma-Aldrich

Anti-BRD7 antibody, Rat monoclonal

clone BRM 2D3, purified from hybridoma cell culture

Synonym(e):

Anti-BP75, Anti-Bromodomain containing 7, Anti-CELTIX1, Anti-NAG4, Monoclonal Anti-BRD7 antibody produced in rat

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12352203
NACRES:
NA.41

Biologische Quelle

rat

Konjugat

unconjugated

Antikörperform

purified from hybridoma cell culture

Antikörper-Produkttyp

primary antibodies

Klon

BRM 2D3, monoclonal

Form

buffered aqueous solution

Mol-Gew.

antigen ~80 kDa

Speziesreaktivität

rat, mouse, monkey, human, bovine, canine

Verpackung

antibody small pack of 25 μL

Methode(n)

immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: 0.5-1.0 μg/mL using HeLa cells extract

Isotyp

IgG2a

UniProt-Hinterlegungsnummer

Versandbedingung

dry ice

Lagertemp.

−20°C

Posttranslationale Modifikation Target

unmodified

Angaben zum Gen

human ... BRD7(29117)

Allgemeine Beschreibung

Monoclonal Anti-BRD7 (rat IgG2a isotype) is derived from the hybridoma BRM 2D3 produced by the fusion of mouse myeloma cells (P3X63Ag8.653) and splenocytes from rat immunized with a fusion protein expressing a fragment of human BRD7. Bromodomain containing (BRD7) is a novel bromodomain gene.

Anwendung

Monoclonal Anti-BRD7 antibody produced in rat has been used in several immunochemical techniques including
  • immunoblotting
  • immunoprecipitation
  • immunocytochemistry

Biochem./physiol. Wirkung

Bromodomain containing (BRD7) inhibits cell growth and cell cycle progression by transcriptional regulation of some cell cycle-related genes as well as some important molecules involved in ras/mitogen-activated protein kinase(MEK)/extracellular-signal-regulated kinase (ERK) and retinoblastoma tumor suppressor protein (RB)/ E2 factor (E2F) pathways. Its transcriptional down regulation has been shown to be critical to the pathogenesis of nasopharyngeal carcinoma (NPC). Specifically, DNA methylation decreases the expression of BRD7 in NPC cells. Furthermore, DNA methylation of BRD7 promoter is increased in the tumor and in matched blood samples from NPC patients than in blood samples from healthy individuals. Therefore, it has been suggested that DNA methylation of BRD7 promoter might act as a potential diagnostic marker in NPC.

Physikalische Form

Lösung in 0.01 M Phosphat-gepufferter Kochsalzlösung pH 7.4, enthält 15 mM Natriumazid.

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

10 - Combustible liquids

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells
Liu H, et al.
BMC Cancer, 8(1), 253-253 (2008)
The transcriptional regulation role of BRD7 by binding to acetylated histone through bromodomain
Cong P, et al.
Journal of Cellular Biochemistry, 97(4), 882-892 (2006)
Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis
Chou J, et al.
Head & Neck, 30(7), 946-963 (2008)
Junichi Yamamoto et al.
Nature chemical biology, 16(11), 1208-1217 (2020-09-23)
The immunomodulatory drug (IMiD) thalidomide and its derivatives lenalidomide and pomalidomide are therapeutic agents used in the treatment of multiple myeloma. Although pomalidomide offers considerable clinical benefits to patients with lenalidomide-resistant multiple myeloma, the molecular mechanisms underlying its superior efficacy

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.